Neurology

  • Adaptive Deep Brain Stimulation for Parkinson Disease: ADAPT-PD Trial

    Adaptive Deep Brain Stimulation for Parkinson Disease: ADAPT-PD Trial

    Deep brain stimulation (DBS) is an established therapy for patients with Parkinson disease (PD) whose symptoms are inadequately controlled with medication. Conventional DBS, however, generally delivers stimulation continuously at a fixed programmed amplitude—even though Parkinson symptoms and underlying brain activity fluctuate throughout the day. The ADAPT-PD trial, published in JAMA Neurology in 2025, evaluated whether…

    read more

  • Amyotrophic Lateral Sclerosis (ALS): Clinical Features, Diagnosis, and Management

    Amyotrophic Lateral Sclerosis (ALS): Clinical Features, Diagnosis, and Management

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons responsible for voluntary movement. Degeneration of both upper motor neurons (UMNs) and lower motor neurons (LMNs) leads to progressive muscle weakness, atrophy, impaired mobility, bulbar dysfunction, and eventually respiratory failure. Although ALS remains a life-limiting disease, earlier recognition, multidisciplinary care, respiratory…

    read more

  • ATLANTIS Trial: Alteplase for Ischemic Stroke 3–5 Hours After Symptom Onset

    ATLANTIS Trial: Alteplase for Ischemic Stroke 3–5 Hours After Symptom Onset

    The ATLANTIS trial, published in JAMA in 1999, evaluated whether intravenous recombinant tissue-type plasminogen activator, also known as rt-PA or alteplase, improves outcomes in patients with acute ischemic stroke when given 3 to 5 hours after symptom onset. At the time, thrombolysis had already shown benefit when administered early after ischemic stroke. ATLANTIS asked an…

    read more